Drug Target Encyclopedia Series (24) —CCR8

Release Time：

2025-12-16 15:19

CCR8 is a G protein–coupled chemokine receptor primarily expressed on tumor-infiltrating regulatory T cells (Tregs).
In cancer immunotherapy, CCR8 has emerged as a highly selective immune checkpoint target, enabling Treg depletion within the tumor microenvironment (TME) while sparing peripheral immune tolerance.

Because of its restricted expression pattern, CCR8 is widely regarded as a next-generation immuno-oncology target.

CCR8 is highly expressed in:

Tumor-infiltrating Tregs (TI-Tregs)
Solid tumors with immunosuppressive TMEs, including:
- Non–small cell lung cancer (NSCLC)
- Breast cancer
- Colorectal cancer
- Ovarian cancer
- Head and neck squamous cell carcinoma (HNSCC)
Select inflammatory and allergic disease contexts

High CCR8 expression correlates with immune evasion, poor prognosis, and resistance to checkpoint inhibitors.

Targeting CCR8 in cancer immunotherapy

🧪 Monoclonal antibodies (mAbs)

Anti-CCR8 antibodies are designed to selectively deplete intratumoral Tregs via ADCC, enhancing effector T-cell activity without systemic autoimmunity.

🧪 Combination immunotherapy

CCR8 blockade is being actively explored in combination with:
• PD-1 / PD-L1 inhibitors
• CTLA-4 antibodies
• Cancer vaccines

to convert “cold” tumors into immune-responsive ones.

🧪 Antibody engineering & Fc optimization

Next-generation CCR8 mAbs focus on Fc-engineering to maximize tumor-restricted Treg depletion.

🧪 mRNA & RNA-based technologies

mRNA tools are increasingly used to:
• Study CCR8-mediated Treg biology
• Validate antibody and CAR constructs
• Model CCR8 expression in immune cells
• Support transient expression for safer immunotherapy research

Key challenges